Becton Dickinson and Company (BDX) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0758871091

Becton, Dickinson and Company, listed as BDX on the New York Stock Exchange, focuses on developing, manufacturing, and distributing a wide range of medical supplies, devices, laboratory equipment, and diagnostic products globally. Their products cater to healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and general consumers.

The company operates across three primary segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical division offers a comprehensive array of products from IV catheters to medication compounding and delivery systems, focusing on patient care and safety.

BD Life Sciences specializes in specimen and blood collection items, along with cutting-edge molecular testing and laboratory automation solutions. Their products include rapid diagnostic assays and advanced systems for microbiology research.

The BD Interventional segment focuses on surgical products like hernia repair materials, surgical infection prevention, and critical care products. They also offer urology solutions and peripheral intervention products for various healthcare needs.

Founded in 1897 and headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company's commitment to innovation and quality has made them a leader in the global healthcare industry. For more information, you can visit their official website at https://www.bd.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Becton Dickinson and Company (BDX) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Becton Dickinson and Company (BDX) - Stock & Dividends

BDX Stock Overview

Market Cap in USD 67,638m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC SubIndustry Health Care Equipment
TER 0.00%
IPO / Inception 1987-01-01

BDX Stock Ratings

Growth 5y 1.01
Fundamental 11.2
Dividend 5.53
Rel. Performance vs Sector -1.60
Analysts 4.27/5
Fair Price Momentum 214.03 USD
Fair Price DCF 256.33 USD

BDX Dividends

Yield 12m 1.59%
Yield on Cost 5y 1.73%
Dividends CAGR 5y 4.02%
Payout Consistency 79.2%

BDX Growth Ratios

Growth 12m -8.17%
Growth Correlation 12m -36%
Growth Correlation 3m 3%
CAGR 5y 1.64%
Sharpe Ratio 12m -0.67
Alpha vs SP500 12m -24.55
Beta vs SP500 5y weekly 0.52
ValueRay RSI 31.89
Volatility GJR Garch 1y 20.64%
Price / SMA 50 -2.2%
Price / SMA 200 -6.14%
Current Volume 779.9k
Average Volume 20d 1054.3k

External Links for BDX Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of BDX stocks?
As of April 25, 2024, the stock is trading at USD 233.83 with a total of 779,855 shares traded.
Over the past week, the price has changed by +0.70%, over one month by -3.24%, over three months by +0.09% and over the past year by -9.40%.
What is the forecast for BDX stock price target?
According to ValueRays Forecast Model, BDX Becton Dickinson and Company will be worth about 233.5 in April 2025. The stock is currently trading at 233.83. This means that the stock has a potential downside of -0.16%.
Issuer Forecast Upside
Wallstreet Target Price 278.5 19.1
Analysts Target Price 301.2 28.8
ValueRay Target Price 233.5 -0.16

The History and Market Status of Becton Dickinson and Company (BDX)

A Brief History

Becton, Dickinson and Company, commonly known as BD, began its journey in 1897. Founded by Maxwell Becton and Fairleigh S. Dickinson, its initial aim was to improve and simplify the process of delivering medications. Starting with glass syringes, BD has significantly grown, enhancing not only the medical field but also healthcare delivery globally. The company achieved many milestones over the years, like the development of the first-ever insulin syringe in 1924, and it has continued innovating in medical technology effectively till today.

Core and Side Businesses

BD's core mission revolves around advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. Its operations span across multiple segments:

  • Medical: Produces devices for medication delivery, diabetes care, and surgical instrument sterilization.
  • Life Sciences: Offers products for collecting and transporting diagnostics specimens, and instruments for cell analysis.
  • Interventional: Focuses on surgery, peripheral intervention, and urology and critical care treatments.

Alongside its primary operations, BD also collaborates with organizations worldwide to tackle global health issues, such as combating antimicrobial resistance and supporting health research and clinical diagnostics.

Current Market Status

As of 2023, BD (NYSE:BDX) continues to hold a significant position in the medical technology industry. Despite the challenges, such as regulatory pressures and global health crises, BD has shown resilience and adaptability. It continues to invest in research and development, aiming to bring forth innovations that can make a real difference in healthcare. The company's commitment to sustainability and addressing global health issues also adds to its reputation, potentially offering a competitive edge in the market. Financially, BD has maintained a steady performance, although the rapidly changing healthcare landscape calls for continuous innovation and strategic partnerships to sustain and enhance its market presence.